Agmatine at a glance
Agmatine is a compound the body makes from arginine, sold in supplements as agmatine sulfate. In the Hammer Labz range it appears in six formulas at 1,000 to 1,500 mg per serving, four of them next to citrulline. The human research is medical, mainly in nerve pain, and we found no trial on training or exercise performance. In the EU, agmatine sulfate is listed as a novel food that is not yet authorised.
Evidence: Human trials, none on exercise · Updated 19 November 2026
What it is
Agmatine forms when the body removes the carboxyl group from arginine, which is why researchers call it decarboxylated arginine. It is also an intermediate in the production of polyamines.
Supplements use agmatine sulfate, the salt of agmatine with sulfuric acid. Five of the six Hammer Labz products below list it as agmatine sulfate; Atomic Strength lists “agmatine” without naming the form.
How it works
Agmatine works differently from citrulline and arginine. In enzyme experiments, it did not act as a raw material for nitric oxide and instead blocked all three nitric oxide synthase enzymes.
Agmatine binds imidazoline and alpha-2 adrenergic receptors, and it also acts on NMDA receptors in the nervous system. A 2025 review of 60 preclinical studies found that agmatine could either raise or lower blood pressure and heart rate. The direction depended on the dose, the route of administration and the receptors involved.
These are cell and animal findings. They do not show what a serving taken by mouth does to blood flow or pump in a trained person.
Evidence
Evidence: Human trials, none on exercise (what our evidence labels mean). Our PubMed search on 19 November 2026 found no published trial of agmatine and exercise performance, pump or blood flow in people. The human studies come from medicine.
The largest is a 2010 randomised, placebo-controlled trial in people with sciatica from a herniated lumbar disc. Participants took 2.67 g of agmatine sulfate a day or placebo for 14 days; 99 were randomised and 61 were analysed. Pain and quality-of-life scores improved in both groups, more so with agmatine.
Before that trial, an open-label phase raised intake step by step from 1.335 to 3.56 g a day. Three participants on the highest intake had mild to moderate diarrhoea and mild nausea, which cleared when they stopped. If you take any medication, check with a doctor before using a product with agmatine.
Smaller open studies without a placebo group have also looked at agmatine sulfate. One followed 11 patients with painful small fibre neuropathy on 2.67 g a day for two months. Another added up to 1.3 g a day to the usual medication of five adults with obsessive-compulsive disorder. One author of the sciatica trial and the neuropathy study co-owns patents on related agmatine products.
None of these studies measured training, strength or endurance. Their results come from patients under medical care and do not carry over to a pre-workout.
Amounts on labels
- Steel X Pump: 1,500 mg agmatine sulfate per 17 g scoop.
- Dragon Blood: 1,500 mg agmatine sulfate per 30 g serving (1.5 scoops).
- Monster Strength: 1,250 mg agmatine sulfate per 10 g scoop (300 g tub); 1,500 mg per 15 g scoop (375 g tub).
- Lion Blood: 1,000 mg agmatine sulfate per 20 ml.
- Crea Nitrix: 1,000 mg agmatine sulfate per 10 g scoop.
- Atomic Strength: 1,000 mg agmatine per 10 g scoop.
The medical studies above used 1.3 to 3.56 g of agmatine sulfate a day, most often 2.67 g, for periods from two weeks to about four months.
Legal and anti-doping status
Status checked on 19 November 2026.
EU food law: the EU novel food catalogue lists agmatine sulfate (entry “Agmatine (4-aminobutyl) guanidine sulfate”) as a “not yet authorised novel food”. Under EU rules, a novel food may be placed on the market only once it is authorised and included in the Union list.
Medicines: we found no medicine containing agmatine in the European Medicines Agency’s database of medicines authorised in the EU and EEA, searched under agmatine and its chemical name.
Anti-doping: agmatine is not named on the 2026 or 2027 WADA List. The List’s class S0 covers pharmacological substances with no current approval for human therapeutic use, and it does not say whether agmatine falls under it. If you compete under anti-doping rules, ask your national anti-doping organisation before using a product that contains it.
Found in
Hammer Labz (more on the range on our Hammer Labz brand page):
- Steel X Pump
- Dragon Blood
- Monster Strength (300 g and 375 g)
- Lion Blood
- Crea Nitrix
- Atomic Strength
Haya Labs
- Agmatine Sulfate 500 mg (60 capsules)
In four of these Hammer Labz formulas, agmatine sits next to citrulline. See our cards on citrulline and citrulline malate and arginine and AAKG.
Sources
- Product labels: Hammer Labz supplement facts panels as listed in November 2026 (Steel X Pump, Dragon Blood, Monster Strength 300 g and 375 g, Lion Blood, Crea Nitrix, Atomic Strength).
- Laube G, Bernstein HG (2017). Agmatine: multifunctional arginine metabolite and magic bullet in clinical neuroscience? Biochem J, 474(15), 2619–2640. PMID: 28747403.
- Galea E, Regunathan S, Eliopoulos V, et al. (1996). Inhibition of mammalian nitric oxide synthases by agmatine, an endogenous polyamine formed by decarboxylation of arginine. Biochem J, 316(Pt 1), 247–249. PMID: 8645212.
- Manole OM, Rusu-Zota G, Bazyani A, et al. (2025). Exploring the Cardiovascular Impacts of Agmatine: A Systematic Review. Med Sci (Basel), 13(4), 255. PMID: 41283257.
- Keynan O, Mirovsky Y, Dekel S, et al. (2010). Safety and Efficacy of Dietary Agmatine Sulfate in Lumbar Disc-associated Radiculopathy. An Open-label, Dose-escalating Study Followed by a Randomized, Double-blind, Placebo-controlled Trial. Pain Med, 11(3), 356–368. PMID: 20447305.
- Rosenberg ML, Tohidi V, Sherwood K, et al. (2020). Evidence for Dietary Agmatine Sulfate Effectiveness in Neuropathies Associated with Painful Small Fiber Neuropathy. A Pilot Open-Label Consecutive Case Series Study. Nutrients, 12(2), 576. PMID: 32102167.
- Salvi JD (2026). Agmatine augmentation in treatment-resistant obsessive-compulsive disorder: a prospective open-label case series. Front Psychiatry, 17, 1745041. PMID: 41717561.
- European Commission. EU Novel Food status catalogue, entry “Agmatine (4-aminobutyl) guanidine sulfate”. Accessed 19 November 2026.
- European Union. Regulation (EU) 2015/2283 on novel foods, Article 6: Union list of authorised novel foods. Text as adopted, legislation.gov.uk. Accessed 19 November 2026.
- European Medicines Agency. Article 57 product data: medicines authorised in the EU and EEA. Data file updated 12 November 2026. Accessed 19 November 2026.
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. In force from 1 January 2026. Accessed 16 November 2026.
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2027. In force from 1 January 2027. Accessed 16 November 2026.
